BrainStorm Cell Therapeutics

BrainStorm Cell Therapeutics is an American biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS). Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.
BrainStorm Cell Therapeutics stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

BrainStorm Cell Therapeutics balance sheet

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

BrainStorm Cell Therapeutics cash flows

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

BrainStorm Cell Therapeutics multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

BrainStorm Cell Therapeutics profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
BrainStorm Cell Therapeutics assets
BrainStorm Cell Therapeutics cash flows

BrainStorm Cell Therapeutics dividend policy

The company doesn't provide dividend

BrainStorm Cell Therapeutics shares

TickerNameTypeNominal valueISINPrice
BCLI:USBrainStorm Cell TherapeuticsCommon share-US10501E2019$1.21
BrainStorm Cell Therapeutics news
16.05.2022
BrainStorm Cell Therapeutics' GAAP loss for 3 months of 2022 was $5.36 million, down 19.5% from $6.662 million in the previous year.
Source: {source} pictogram ir.brainstorm-cell.com
Pictogram next
28.03.2022
BrainStorm Cell Therapeutics' GAAP loss for 2021 was $24.457 million, down 23.1% from $31.811 million the previous year.
Source: {source} pictogram ir.brainstorm-cell.com
Pictogram next
15.11.2021
BrainStorm Cell Therapeutics' GAAP loss for 9M 2021 was $18.267 million, down 8.6% from $19.996 million in the prior year.
Source: {source} pictogram ir.brainstorm-cell.com
Pictogram next
05.08.2021
BrainStorm Cell Therapeutics' GAAP loss for 6 months of 2021 was $12.931 million, down 16.6% from $15.508 million in the prior year.
Source: {source} pictogram ir.brainstorm-cell.com
Pictogram next
All BrainStorm Cell Therapeutics news
General information
Company nameBrainStorm Cell Therapeutics
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address1325 Avenue of Americas Suite 320 New York, NY 10019 United States
Mailing address1325 Avenue of Americas Suite 320 New York, NY 10019 United States
Websiteir.brainstorm-cell.com
Information disclosurewww.sec.gov